Blend Labs Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
BLND$1.08+9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity
| Year Ended December 31, 2023 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redeemable Noncontrolling Interest · Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||||||||
| Shares · Amount | ||||||||||||
| Balances as of December 31, 2022 | $40,749 | 240,931 | $2 | $1,286,815 | $(708) | $(1,162,937) | $123,172 | |||||
| Issuance of common stock upon exercise of stock options, net of repurchases | — | 274 | — | 460 | — | — | 460 | |||||
| Vesting of early exercised stock options | — | — | 1,446 | — | — | 1,446 | ||||||
| Vesting of restricted stock units | — | 13,531 | — | — | — | — | — | |||||
| Shares withheld related to net share settlement of equity awards | — | (4,826) | — | (6,171) | — | — | (6,171) | |||||
| Stock-based compensation | — | — | — | 46,021 | — | — | 46,021 | |||||
| Unrealized gain on investments in marketable securities | — | — | — | — | 1,030 | — | 1,030 | |||||
| Foreign currency translation gain | — | — | — | — | 119 | — | 119 | |||||
| Accretion of redeemable noncontrolling interest to redemption value | 6,627 | — | — | (6,627) | — | — | (6,627) | |||||
| Net loss | (1,186) | — | — | — | — | (178,693) | (178,693) | |||||
| Balances as of December 31, 2023 | $46,190 | 249,910 | $2 | $1,321,944 | $441 | $(1,341,630) | $(19,243) | |||||
Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity (Continued)
| Year Ended December 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|
| Redeemable Noncontrolling Interest · Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||
| Shares · Amount | |||||||
| Balances as of December 31, 2021 | $35,949 | 230,324 | $2 | $1,218,213 | $(808) | $(442,765) | $774,642 |
| Issuance of common stock upon exercise of stock options, net of repurchases | — | 2,706 | — | 3,548 | — | — | 3,548 |
| Vesting of early exercised stock options | — | — | — | 4,060 | — | — | 4,060 |
| Vesting of restricted stock units | — | 7,901 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 109,702 | — | — | 109,702 |
| Unrealized loss on investments in marketable securities | — | — | — | — | (135) | — | (135) |
| Foreign currency translation gain | — | — | — | — | 235 | — | 235 |
| Accretion of redeemable noncontrolling interest to redemption value | 48,438 | — | — | (48,438) | — | — | (48,438) |
| Other | — | — | — | (270) | — | — | (270) |
| Net loss | (43,638) | — | — | — | — | (720,172) | (720,172) |
| Balances as of December 31, 2022 | $40,749 | 240,931 | $2 | $1,286,815 | $(708) | $(1,162,937) | $123,172 |
Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity (Continued)
| Year Ended December 31, 2021 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Redeemable Noncontrolling Interest · Founders Preferred Stock and Convertible Preferred Stock · Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||||
| Shares · Amount · Shares · Amount | |||||||||
| Balances as of December 31, 2020 | $— | 122,379 | $385,225 | 47,948 | $1 | $50,968 | $(5) | $(272,852) | $163,337 |
| Issuance of Series G Convertible Preferred Stock, net of issuance costs of $299 | — | 22,419 | 309,701 | — | — | — | — | — | 309,701 |
| Exercise of performance-based convertible preferred stock warrants | — | 2,075 | 8,014 | — | — | — | — | — | 8,014 |
| Issuance of common stock upon exercise of stock options, net of repurchases | — | — | — | 12,927 | — | 13,397 | — | — | 13,397 |
| Vesting of early exercised stock options | — | — | — | — | — | 5,023 | — | — | 5,023 |
| Vesting of performance-based convertible preferred stock warrants | — | — | — | — | — | 118 | — | — | 118 |
| Vesting of restricted stock units | — | — | — | 108 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | — | 70,844 | — | — | 70,844 |
| Unrealized loss on investments in marketable securities, net | — | — | — | — | — | — | (794) | — | (794) |
| Repayment of employee promissory note collateralized by common stock | — | — | — | — | — | 2,881 | — | — | 2,881 |
| Noncontrolling interest recognized in connection with business combination | 33,748 | — | — | — | — | — | — | — | — |
| Issuance of common stock in connection with initial public offering, including partial exercise of the underwriter’s option to purchase additional shares, net of underwriting discounts and issuance costs | — | — | — | 22,468 | — | 366,684 | — | — | 366,684 |
| Conversion of convertible preferred stock to common stock in connection with initial public offering | — | (146,873) | (702,940) | 146,873 | 1 | 702,939 | — | — | — |
| Issuance of warrant in connection with the Credit Agreement | — | — | — | — | — | 6,789 | — | — | 6,789 |
| Accretion of redeemable noncontrolling interest to redemption value | 1,430 | — | — | — | — | (1,430) | — | — | (1,430) |
| Foreign currency translation loss | — | — | — | — | — | — | (9) | — | (9) |
| Net income (loss) | 771 | — | — | — | — | — | — | (169,913) | (169,913) |
| Balances as of December 31, 2021 | $35,949 | — | $— | 230,324 | $2 | $1,218,213 | $(808) | $(442,765) | $774,642 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.